Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,852 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Matsumoto M, et al. Among authors: matsuda k. Int J Hematol. 2021 Jun;113(6):777-784. doi: 10.1007/s12185-021-03139-1. Epub 2021 Apr 15. Int J Hematol. 2021. PMID: 33856638 Clinical Trial.
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K. Takezako N, et al. Among authors: matsuda k. Int J Hematol. 2020 Nov;112(5):640-649. doi: 10.1007/s12185-020-02953-3. Epub 2020 Sep 19. Int J Hematol. 2020. PMID: 32949374
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, Tomita Y, Oyama M, Masumori N, Kojima T, Matsumoto H, Chen M, Li M, Matsuda K, Tanaka Y, Rini BI, Uemura H. Tamada S, et al. Among authors: matsuda k. Int J Clin Oncol. 2022 Jan;27(1):154-164. doi: 10.1007/s10147-021-02014-7. Epub 2021 Nov 20. Int J Clin Oncol. 2022. PMID: 34800178 Free PMC article. Clinical Trial.
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Konishi M, Imoto K, Matsuyama H. Shimabukuro T, et al. Among authors: matsuda k. Int J Clin Oncol. 2013 Feb;18(1):62-7. doi: 10.1007/s10147-011-0344-x. Epub 2011 Nov 3. Int J Clin Oncol. 2013. PMID: 22068464
Comparison of MRI findings for predicting massive hemorrhage during cesarean section in patients with placental malposition: partial placental volume of lower uterine segment is an accurate and objective indicator.
Kuwamura H, Terayama T, Hamabe F, Edo H, Matsuda K, Miyamoto M, Takano M, Shinmoto H. Kuwamura H, et al. Among authors: matsuda k. Arch Gynecol Obstet. 2025 Jan 28. doi: 10.1007/s00404-024-07909-0. Online ahead of print. Arch Gynecol Obstet. 2025. PMID: 39870918
3,852 results